Rohto Pharmaceutical Co., Ltd.

Rohto Pharmaceutical Co., Ltd.

15.80
EUR
-0.20
(-1.25%)
Nov 12Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
621.2
669.64
732.27
679.04
754.04
805.9
825.92
793.6
875.1
1,046.13
1,187.25
1,354.78
1,521.15
- -
Basic EPS, GAAP
38.57
38.03
40.02
43.97
40.77
43
67.56
73.39
92.61
115.62
135.61
135.38
151.56
- -
Free Cash Flow per Basic Share
51.53
31.48
29
41.5
60.14
65.06
55.27
42.54
69.79
92.12
111.05
115.7
95.31
- -
Dividend per Share
9.12
9.03
10.02
10.01
11
11
13.5
13
15
20.5
24
31.04
41
- -
Book Value per Share
433.25
484.58
487.09
517.93
560.41
575.89
610.51
683.38
781.97
918.6
1,079.71
1,165.54
1,335.72
- -
Tangible Book Value per Share
420.78
465.32
471.7
506.24
542.38
560.25
588.02
648.78
740.15
876.69
1,039.31
850.3
964.43
- -
Basic Weighted Avg Shares
232
227
227
228
228
228
228
228
228
228
228
228
226
226
Sales/Revenue/Turnover
144,082
151,994
166,477
154,599
171,795
183,672
188,375
181,053
199,646
238,664
270,840
308,625
343,725
- -
Operating Margin (%)
11.68
8.66
9.42
10
11.11
11.33
11.98
12.7
14.54
14.23
14.79
12.39
11.96
- -
Depreciation Expense
5,926
6,341
6,448
5,923
5,914
6,404
6,937
6,748
7,689
7,801
8,687
13,301
17,377
- -
Net Income, GAAP
8,947
8,631
9,098
10,011
9,289
9,799
15,410
16,743
21,127
26,377
30,936
30,841
34,247
- -
Effective Tax Rate (%)
38.71
37.26
36.47
32.12
44.49
39.76
29.67
27.11
23.99
22.92
24.38
26.82
26.49
- -
Profit Margin (%)
6.21
5.68
5.47
6.48
5.41
5.34
8.18
9.25
10.58
11.05
11.42
9.99
9.96
- -
Working Capital
26,338
36,085
42,395
47,526
48,718
55,642
68,589
76,600
92,818
110,084
127,672
123,271
121,925
- -
LT Debt
1,666
1,074
994
1,765
1,702
1,424
5,190
5,787
13,350
7,516
5,190
50,374
35,502
- -
Total Equity
98,626
110,513
111,268
118,435
128,437
132,187
140,030
156,611
183,992
215,076
247,033
280,734
320,172
- -
Return on Invested Capital (%)
9.53
7.05
8.18
8.47
7.98
8.94
11.02
10.35
11.63
11.86
12.18
9.18
8.25
- -
Return on Capital (%)
8.64
7.69
7.79
8.41
7.23
7.27
10.98
10.78
11.49
12.27
12.65
10.72
9.75
- -
Return on Common Equity (%)
9.33
8.29
8.24
8.75
7.56
7.57
11.39
11.34
12.64
13.6
13.57
12.1
12.12
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
20,142
24,742
- -
LT Borrowings
26,939
28,188
- -
LT Finance Leases
- -
7,314
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
226
226
226
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
222,228
239,274
- -
Cash, Cash Equivalents & STI
78,244
86,816
- -
Accounts Receivable, Net
48,816
52,684
- -
Inventories
63,120
65,677
- -
Total Current Liabilities
102,277
117,349
- -
Payables & Accruals
- -
- -
- -
ST Debt
20,142
24,742
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.25%
15.38%
14.05%
Free Cash Flow
16.09%
20.47%
-18.28%
Net Income, GAAP
15.33%
15.81%
11.04%
Sales/Revenue/Turnover
7.82%
13.72%
11.37%
Total Cash Common Dividend
- -
25.86%
31%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
308,625
2026
- -
- -
- -
- -
343,725
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
135.38
2026
- -
- -
- -
- -
151.56
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
31.04
2026
- -
- -
- -
- -
41
2027
- -
- -
- -
- -
- -

Company Description

CEO
Kunio Yamada
Full Time Employees
9,292
Sector
Consumer non-durables
Industry
Household/Personal care
Address
1-8-1, Tatsumi-nishi Osaka OS Japan 544-8666
IPO Date
Oct 2, 1961
Business
Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide; its core offerings include eye care products such as eye drops, contact lens care solutions, and eyewash; skin care items comprising face washes, lotions, creams, lip balms, sunscreens, and functional cosmetics; internal medicines like digestive aids and herbal remedies; over-the-counter pharmaceuticals encompassing ophthalmic, dermatological, gastrointestinal, and diagnostic drugs as well as Chinese herbal medicines and supplements; oral care products including toothpaste and mouthwashes; and additional services such as beauty counters for health consultations, diagnostic reagents, investment management, and contract development and manufacturing. The company operates primarily in the over-the-counter pharmaceuticals, consumer healthcare, and cosmetics segments, targeting consumers seeking health and beauty solutions, with a strong presence in Japan and international markets across Asia, North America, Europe, and beyond through subsidiaries and production facilities in the US, UK, China, Vietnam, Hong Kong, and Indonesia. Founded in 1899 as Shintendo Yamada Anmin Pharmacy and incorporated in 1949 with its current name, Rohto Pharmaceutical is headquartered in Ikuno-ku, Osaka, Japan, and lists on the Tokyo Stock Exchange Prime Market. Recent developments include the completion of its acquisition of Eu Yan Sang, a health and wellness platform, from Righteous Crane Holding in partnership with Mitsui in 2025 to bolster its natural health offerings; the acquisition of an additional 51% stake in Mono chem-pharm Produkte GmbH, an Austrian eye care firm, for 30 million euros in June 2024 to expand into Europe; and the purchase of Obagi trademark rights in Japan from Waldencast plc for $82.5 million in November 2025 to strengthen its skincare portfolio.